Arcalyst is a targeted inhibitor of interleukin-1 (IL-1), the key driver of inflammation in CAPS. Regeneron expects to launch Arcalyst, its first commercial product, within the next 30 days.
Leonard Schleifer, Regeneron’s president and CEO, said: “This approval exemplifies company’s commitment to discover, develop, and commercialize important medicines for patients suffering from serious diseases, such as CAPS.”